A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma. Background: Recurrence will occur in about 20% of all primary melanoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback